-
About UsWe are a company specializing in the research, development, and production of pharmaceutical and functional chemicals, dedicated to delivering innovative and high-quality products.
-
Main BusinessOur core focus is on the research and production of pharmaceutical chemicals and related products.
-
ProductsWe specialize in the technological breakthroughs, production, and sales of high-value specialty active pharmaceutical ingredients, small molecule chemical drugs, and pharmaceutical intermediates.
-
ESGPlacing a strong emphasis on sustainable development and continuously improve our quality management system, we actively implement these principles in our production processes and uphold our corporate social responsibility.
-
Join UsFind the job you’re suited to. Jingyu Group urgently needs passionate individuals like you who love pharmaceuticals and chemistry to join us!
Medicinal Chemistry
Baiyin Whale Pharmaceutical Co., Ltd
Hereinafter Referred To As: Whale Pharma
Whale Pharma is located in Baiyin City, Jingyuan County, Gansu Province, China, in the Baiyin Liuchuan Industrial Zone. Its predecessor was Baiyin Yier Fine Chemical Co., Ltd. (referred to as "Yier Chemical"). Established in 2015, Yier Chemical primarily focused on the production and sales of pharmaceutical intermediates. In 2020, Yier Chemical underwent a strategic acquisition by Beijing Jingyu Furui Technology Group Co., Ltd. (Whale Corporation), resulting in a comprehensive upgrade from a fine chemical company producing pharmaceutical intermediates to a high-tech pharmaceutical enterprise specializing in the production of high-value specialty pharmaceutical active ingredients.
In 2020,Whale Pharma accelerated its industrial upgrading and made significant adjustments to development strategies, business philosophies, product positioning, personnel configuration, and production facilities. In 2021, Whale Pharma obtained the Drug Production License, becoming a pharmaceutical enterprise with this qualification in the Liuchuan Industrial Park, Jingyuan County.
Leveraging the strong research and development capabilities and business expansion capacities of the group, Whale Pharma focuses on the development of human-use specialty pharmaceutical active ingredients. Following the development strategy of "R&D in Beijing, production in Jingyuan, and sales worldwide", the company aims to become a leading global pharmaceutical industrial enterprise in China.
Gansu Whale Luck Pharmaceutical Co., Ltd
Hereinafter Referred To As: Whale Luck
Whale Luck, established on March 11, 2022, is a high-tech pharmaceutical company specializing in the production of high-value specialty pharmaceutical active ingredients.
The total planned area for this project is approximately 65.4 acres (about 43,610 square meters), with a total building area of 27,346.26 square meters. The capacity-building area is 29,651.26 square meters, and the building site area is 18,302.26 square meters. The green area covers 5,198 square meters. The building coverage ratio is 62.71%, with a plot ratio of 0.6799, and a green area ratio of 3.285%. The proportion of supporting service facilities is 3.382%.
After reaching full production, the project plans to annually produce 3,000 tons of pharmaceutical intermediates, including 1,000 tons of aminoditol, and 500 tons each of naproxen and Y06 products.
With the strong research and development capabilities and business expansion capacities of Whale Corporation, the project aims to deeply cultivate the pharmaceutical intermediate business. Following the development strategy of "production in Baiyin, research and development in Beijing, and sales worldwide", it aspires to become a leading global pharmaceutical intermediate industrial enterprise in China.
Upon completion, the project will contribute over 340 million yuan in annual output value to Baiyin City, creating employment opportunities for more than 200 people. It will also promote the development of the pharmaceutical and chemical industry in Baiyin City, attract top domestic pharmaceutical and chemical technology resources and talents, and enhance the city's scientific research and development capabilities.
Dermaliq
Dermaliq Therapeutics, Inc
In January 2022, Germany's Novaliq, Bencis Capital Partners, and Beijing Jingyu Furui Technology Group jointly established Dermaliq Therapeutics, Inc. (Dermaliq) and signed a $15 million Series A financing round.
Dermaliq is a pharmaceutical development company based in Delaware. Novaliq, an existing shareholder of Dermaliq, has transferred and granted intellectual property rights related to the field of dermatology to Dermaliq.
Dermaliq is developing a next-generation skin delivery method using its core technology platform, hyliQ®. This platform focuses on lipophilic "supra-liquid" semi-fluorinated alkane and aims to develop innovative transdermal formulations. The technology significantly improves the bioavailability of drugs, offers good compliance, and maintains a desirable post-application skin appearance. HyliQ® can greatly enhance drug permeation efficiency and is a major breakthrough in transdermal drug delivery, as it has excellent safety due to its lack of involvement in metabolic processes within the human body. The funds from this financing round will be used for three Phase 1/2a clinical trials to analyze the safety and efficacy of the investigational products and bring these novel dermatological medications to the market, improving the lives of millions of patients:
- DLQ01, a liquid candidate drug for topical treatment of androgenetic alopecia in both women and men. It targets prostaglandin E2 (PGE2) receptors in hair follicles through specific follicular drug delivery.
- DLQ02, a novel liquid topical therapy utilizing a calcium-activated neurophosphatase inhibitor for plaque psoriasis, particularly in difficult-to-treat areas.
- DLQ03, a broad-spectrum liquid antibiotic candidate for localized treatment of bacterial skin and soft tissue infections, including reducing antibiotic-resistant strains.
Dermaliq has already completed preclinical studies for the above three products and has validated the ability of hyliQ® to enhance local drug permeation in models.
Related information
-
- In November 2019, Dermaliq shareholder Novaliq Company granted Hengrui Pharmaceuticals an exclusive patent for the clinical development, production, and market sales of dry eye medication treatment.
- In February 2023, Hengrui Pharmaceuticals applied for the launch of a Class 1 new drug SHR8058 eye drops (also known as NOV03) to the Drug Evaluation Center (CDE) of the China National Drug Administration and was accepted for use in the treatment of dry eye diseases related to meibomian gland dysfunction.